World Investment Advisors Acquires 3,862 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

World Investment Advisors boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 138.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,653 shares of the medical equipment provider's stock after acquiring an additional 3,862 shares during the period. World Investment Advisors' holdings in Zimmer Biomet were worth $753,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at about $204,000. Proficio Capital Partners LLC bought a new stake in Zimmer Biomet in the fourth quarter valued at about $55,000. Atria Investments Inc increased its stake in Zimmer Biomet by 54.0% in the fourth quarter. Atria Investments Inc now owns 8,358 shares of the medical equipment provider's stock valued at $883,000 after acquiring an additional 2,929 shares during the period. Raymond James Financial Inc. bought a new stake in Zimmer Biomet in the fourth quarter valued at about $21,234,000. Finally, Larson Financial Group LLC increased its stake in Zimmer Biomet by 10.6% in the fourth quarter. Larson Financial Group LLC now owns 3,769 shares of the medical equipment provider's stock valued at $398,000 after acquiring an additional 362 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider directly owned 20,424 shares in the company, valued at $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.39% of the stock is currently owned by insiders.

Zimmer Biomet Trading Down 1.3%

ZBH traded down $1.27 during mid-day trading on Friday, hitting $93.88. The stock had a trading volume of 1,573,583 shares, compared to its average volume of 1,827,963. The stock's fifty day simple moving average is $93.21 and its 200-day simple moving average is $101.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. The firm has a market capitalization of $18.57 billion, a price-to-earnings ratio of 20.77, a price-to-earnings-growth ratio of 2.17 and a beta of 0.71. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same period last year, the business posted $1.94 earnings per share. The firm's quarterly revenue was up 1.1% on a year-over-year basis. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.02%. Zimmer Biomet's payout ratio is 21.24%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on ZBH shares. Canaccord Genuity Group lowered their target price on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. JMP Securities lowered their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Raymond James Financial decreased their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Finally, Robert W. Baird decreased their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and an average price target of $110.00.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.